Pure Global
NCT06204419

A Phase I Study of XH-S002 in Healthy Volunteers

A Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of XH-S002 After Single Ascending Doses, Multiple Ascending Doses and Evaluation of Food Effects in Healthy Volunteers
S-Infinity Pharmaceuticals Co., Ltd·Phase 1·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Healthy Adults
Drug/Device/Intervention
XH-S002 （A）
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
S-Infinity Pharmaceuticals Co., Ltd
Location
Beijing, China
Timeline & enrollment
Phase
Phase 1
Start date
Dec 26, 2023
End date
Oct 01, 2024
Enrollment
86 participants
Primary outcome

To access the safety and tolerability of single ascending dosed of XH-S002 in healthy adults.,To access the safety and tolerability of multiple ascending dosed of XH-S002 in healthy adults.

Summary

The purpose of the study is to assess the safety, tolerability and pharmacokinetics of
 XH-S002 in healthy volunteers under SAD (Single ascending dose) and MAD (Multiple ascending
 dose) studies. In addition, this study evaluates the food effects of XH-S002.

ICD-10 classifications
ObesityHealthy person accompanying sick personObesity, unspecifiedRoutine general health check-up of inhabitants of institutionsLifestyle-related condition
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06204419
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06204419 through Pure Global AI's free database. This Phase 1 trial is sponsored by S-Infinity Pharmaceuticals Co., Ltd and is currently Recruiting. The study focuses on Healthy Adults. Target enrollment is 86 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.